MDMA-assisted therapy for PTSD

1. Introduction

Version followed: the MAPS treatment manual as published in the Revised Teaching Manual Draft (Ruse, Mithoefer, Jerome, Doblin, Gibson; revised 23 Oct 2010), with the session structure taken from the MAPP1 phase 3 protocol (Amendment 4, 22 May 2020). The current version is A Manual for MDMA-Assisted Therapy in the Treatment of PTSD, Version 8.1 (22 Aug 2017; Michael Mithoefer, Annie Mithoefer, Lisa Jerome, June Ruse, Rick Doblin, Elizabeth Gibson, Marcela Ot'alora G., Evan Sola). MAPS's manual page lists these details, says the manual is meant only for approved clinical trials, and links an Adherence Ratings Manual (v6, 3 Aug 2021) and an Integration Guide. The v8.1 PDF itself is not drawn on here. Where v8.1 may differ from the 2010 text, this guide marks it [uncertain]. [source: MAPS manual page; 2010 manual; MAPP1 protocol]

Sources include: the v8.1 manual's title, date and authors (MAPS manual page); the complete response letter's date and main findings, as reported from the published letter (Lykos press release; HCPLive; Psychiatric Times); the August 2026 resubmission as reported, and the fact that neither the company nor the FDA has confirmed it (Psychedelic Alpha; HCPLive; Psychedelics Today); the Canadian civil claim (B.C. Supreme Court filing), MAPS's 2019 statement and payment, and Health Canada's 2022 review (CBC). Not confirmed: the v8.1 text itself (the 2010 manual is used instead); the FDA's acceptance of the resubmission and any goal date; the College of Physicians and Surgeons of B.C. outcome for Dr Dryer; two of the three 2024 retraction notices; US scheduling and Australian TGA status. The CRL is known only through press reports, not the FDA PDF.

What it is. MDMA-assisted therapy (MDMA-AT; called "MDMA-assisted psychotherapy" in older documents) is a manualised psychotherapy for chronic PTSD. A two-therapist team gives three kinds of session: non-drug preparatory sessions, all-day "experimental" sessions in which the participant has received MDMA in a medically supervised research setting, and non-drug integrative sessions. The manual says it is a structure, not a complete script, and that it leaves room for clinical judgement within the method's spirit. [source: 2010 manual]

How change is thought to happen. The manual's central premise is that the participant has an innate capacity to heal, called the "inner healing intelligence". The therapists support it and do not direct it, trusting "the wisdom and timing of the inner healing process" (2010 manual). The medicine is presented as a tool, not the therapy itself. The stated therapeutic aim is to keep the participant within a manageable emotional range while engaging traumatic material, without dissociating or becoming overwhelmed, and then to bring insights into daily life through integration. [source: 2010 manual; MAPP1 protocol]

Legal and regulatory status (checked October 2026).

• United States: not approved. The developer was MAPS Public Benefit Corporation, renamed Lykos Therapeutics in January 2024 and rebranded Resilient Pharmaceuticals in August 2025 alongside a recapitalisation. It submitted a New Drug Application (NDA 215455, midomafetamine) in December 2023, and the FDA granted Priority Review. [source: Blossom stakeholder profile; Psychiatric Times/Drug Topics headlines, Feb 2024] [uncertain: the renaming dates come from the Blossom profile only; Psychedelic Alpha (Aug 2026) confirms only that Resilient was "formerly Lykos Therapeutics"]
• June 2024 advisory committee. On 4 June 2024 the FDA Psychopharmacologic Drugs Advisory Committee voted 9–2 that efficacy had not been shown and 10–1 that benefits did not outweigh risks. Lykos's own press release confirms the meeting date and says the issues in the CRL echoed those raised there. [source: Patsnap Synapse, 28 Jun 2024; Lykos press release, 9 Aug 2024]
• August 2024 complete response letter. The letter is dated 8 August 2024, per the FDA document cited by HCPLive and Psychiatric Times. Lykos announced it on 9 August 2024. Lykos said the FDA had asked for an additional phase 3 trial and that the application "could not be approved based on data submitted to date"; its CEO Amy Emerson called the request "deeply disappointing". On 4 September 2025 the FDA published it as one of 89 previously unpublished CRLs. HCPLive (15 Sep 2025) reports three main concerns:
  • adverse events that participants or staff considered "positive" or "favorable", including those relevant to abuse potential, were not collected;
  • durability was not tested beyond 18 weeks, and the long-term follow-up study (MPLONG) had design flaws;
  • about 40% of participants had used MDMA before, which raised selection bias and functional unblinding.
  • For a new trial, the FDA recommended a randomised double-blind design, exclusion of prior MDMA users, pre-specified retreatment criteria, full adverse-event reporting and a third-party data audit. Psychiatric Times adds that the letter suggested considering a low-dose comparison arm. [source: Lykos press release via BioSpace, 9 Aug 2024; HCPLive, 15 Sep 2025; Psychiatric Times, 5 Sep 2025] [uncertain: the FDA PDF itself is not drawn on; HCPLive's text says 9 Aug 2024, but its reference list gives 8 Aug 2024]
• August 2026 resubmission (reported, not confirmed by the company). On 9 August 2026 Psychedelic Alpha reported that Resilient had resubmitted the NDA. Its source was anonymous "sources familiar with the filing". Its 12 August follow-up said "Resilient has not publicly discussed the resubmission". According to Psychedelic Alpha, there is no new in-house phase 3 trial. The resubmission instead draws on:
  • other groups' studies, including a small VA study with long-term follow-up;
  • a new phase 1 safety study in healthy volunteers (NCT07584720);
  • an audit of the phase 3 data.
  • On 10 August 2026 MAPS said it initiated and funded the research the application builds on. MAPS says it has no operational role at Resilient. HCPLive (10 Aug 2026) and Psychedelics Today (18 Aug 2026; the company "has apparently resubmitted") rely on the same reporting. In July 2026 the FDA finalised its guidance Psychedelic Drugs: Considerations for Clinical Investigations. [source: Psychedelic Alpha, 12 Aug 2026; HCPLive, 10 Aug 2026; Psychedelics Today, 18 Aug 2026]
• Still unknown. None of the reports (the latest dated 18 Aug 2026) says the FDA accepted the resubmission. None gives a resubmission class or a PDUFA goal date, and no statement from the company or the FDA is cited. As of 14 Oct 2026, treat the resubmission as reported but unconfirmed, and its outcome as pending. [uncertain]
• US scheduling. Outside FDA-authorised research, MDMA remains a Schedule I controlled substance under US federal law. [uncertain: well established]
• Other jurisdictions. Australia has allowed authorised psychiatrists to prescribe MDMA for PTSD since July 2023. [uncertain: confirm with the TGA] In Canada, the 2015 Vancouver phase 2 study ran under Health Canada approval [source: CBC, 2022]. In April 2022 Health Canada said it was reviewing all MDMA trials [source: CBC, 8 Apr 2022]. Other Canadian access routes are [uncertain].
• What this means for clinicians. MDMA-AT is lawful only inside authorised trials or regulated programmes. With clients who use MDMA elsewhere, the clinician's role is harm reduction and integration support (see 4.27), never facilitation.

2. Framework

[source: MAPP1 protocol (structure, timings, check-ins); 2010 manual (phase goals)]

• Total course. Phase 3 (MAPP1): about 12 weeks of treatment after the 3 preparatory sessions, i.e. 3 medicine sessions each followed by 3 integrative sessions. The 2010 phase 2 manual described daily phone contact for about a week after each session; the phase 3 protocol uses scheduled check-ins over two weeks. [source: 2010 manual; MAPP1]
• Recording. Participants must agree to video recording of all sessions. [source: MAPP1]
• Stopping. If a participant develops an exclusion criterion, medicine sessions stop and integrative sessions continue. Participants who leave early get an exit plan. Participants may withdraw at any time without judgement. [source: MAPP1]
• Training. Therapy teams are trained on the manual and supervised by the sponsor through open-label lead-in protocols. The MAPP1 protocol notes that one phase 2 study was stopped early partly because therapy-team training was insufficient. MAPS also publishes an Adherence Ratings Manual (Version 6, 3 Aug 2021). [source: MAPP1; MAPS manual page] [uncertain: the adherence manual]

Published eligibility (MAPP1; summarised, not exhaustive).

• Inclusion: adults; current severe PTSD lasting at least six months; agreement to recording, to naming a support contact and to reporting medical events. Some well-controlled conditions (for example controlled hypertension or stable type 2 diabetes) are allowed with medical-monitor approval.
• Exclusion: inability to consent; ongoing compensation litigation tied to PTSD symptoms; likely re-exposure to the trauma; significant ecstasy use or a prior MAPS MDMA trial; primary psychotic disorder, bipolar I disorder, dissociative identity disorder, and specified personality disorders; current serious suicide risk or recent ideation or behaviour above set thresholds (past attempts alone do not exclude); significant cardiovascular, arrhythmia or QT-related conditions; liver disease; a history of hyponatraemia or hyperthermia; low body weight; pregnancy or nursing; recent ketamine use.
• Earlier phase 2 exclusions: the 2010 manual also lists active substance dependence and recent self-harm, and notes that DID and borderline personality disorder were excluded in early studies. [source: MAPP1; 2010 manual]

3. Guiding principles

[source: 2010 manual unless marked]

• Inner healing intelligence. Trust the participant's own healing process and timing. In practice: do not push towards a set outcome; your job is to support what emerges.
• Medicine as a tool, not the therapy. In practice: frame all change as the participant's own work, and expect the process to be non-linear and to surprise you.
• Follow more than lead. In practice: mostly follow. Step in only when the participant intellectualises, gets stuck or avoids, and then offer an invitation ("would you be willing to…"), not an instruction.
• Respect resistance. In practice: treat avoidance as protective. Explore it gently and collaboratively rather than pushing past it.
• Empathic presence, including silence. In practice: stay attuned during long non-verbal stretches. Balance active help with quiet observation.
• Stay in a tolerable range. In practice: help the participant stay with feelings without suppressing or escaping them, and use breath, body and reassurance before anything more active. [also MAPP1]
• Self-direction over interpretation. In practice: do not impose interpretations. Let meaning come from the participant.
• Non-pathologising openness. In practice: accept unusual, transpersonal or "multiplicity" experiences without labelling them as illness. The manual values familiarity with parts-based approaches such as Internal Family Systems.
• Two-therapist team, ideally one woman and one man. In practice: both are usually present for the whole session; at least one is always present.
• Consent governs all touch. In practice: agree touch in advance and honour "stop" at once, except when touch is needed to prevent physical harm. Never any sexual contact.
• Safety before study goals. In practice: the participant's wellbeing takes precedence over the protocol. Participation is voluntary.
• Therapist self-awareness. In practice: the manual asks for comfort with intense emotion and non-ordinary states and for firm boundaries; it recommends that therapists have had such states themselves (ideally in a therapeutic setting or through a non-drug method). Notice your own pull to rescue, direct or merge.
• Integration starts at preparation. In practice: talk from session 1 about how insights will be carried into daily life.
• Positive experiences heal too. In practice: give pleasurable and connected experiences as much attention as painful ones.

4. Intervention inventory

[source: 2010 manual for content; MAPP1 for structure; anything else is marked] Everything here is the psychotherapy and safety frame. Drug handling, dosing and medical monitoring belong to the licensed medical team under the protocol and are deliberately not described.

Preparation phase

4.1 Screening and eligibility assessment

• Purpose: to confirm the diagnosis and rule out the published medical and psychiatric exclusions before anyone commits to treatment.
• Steps:
  1. Confirm the PTSD diagnosis, its severity and how long it has lasted, using the protocol's measures.
  2. Take a psychiatric history covering psychosis, bipolar I disorder, dissociative disorders, personality disorders, substance use and suicidality (C-SSRS).
  3. Refer to the medical team for cardiovascular, hepatic and other screening, and for review and any tapering of current medication.
  4. Check for ongoing litigation and for the risk of re-exposure to the trauma.
  5. Obtain a named support contact.
• Example language (illustrative): "Before we can decide together whether this is right for you, the medical team and I need to understand your health history in some detail."
• Watch for: pressure from the person (or from you) to minimise exclusions because hopes are high; risk that is not disclosed. If a criterion appears later, sessions stop and integration continues. [source: MAPP1]

4.2 Informed consent as a process

• Purpose: voluntary, informed agreement. The manual puts participant safety above study goals.
• Steps:
  1. Take consent at the screening visit.
  2. Explain recording of all sessions, the overnight stay, the right to withdraw at any time without judgement, the risks, and that change may be non-linear, including temporary worsening.
  3. Revisit consent at every phase. [synthesis: revisiting consent at each phase]
• Example language (illustrative): "You can stop at any point, and nobody here will hold it against you."
• Watch for: deference to authority, especially with trauma survivors; consent given only to please. [synthesis] [source: MAPP1; 2010 manual]

4.3 Building the alliance, including therapist self-disclosure

• Purpose: the trust that lets the participant go inward safely.
• Steps:
  1. Both therapists introduce themselves and describe their background and commitment to the work.
  2. Use some self-disclosure to build trust.
  3. Listen more than you explain.
• Example language (illustrative): "Let us tell you a little about who we are and why we do this work."
• Watch for: disclosure that serves your needs rather than the alliance, and an early idealised attachment. Keep disclosure brief and relevant. [synthesis: caution on self-disclosure]

4.4 History and information gathering

• Purpose: a shared map of the trauma, symptoms and resources.
• Steps: use open questions about symptoms, the traumatic event(s), prior treatments, medical and family history, and past experience of psychedelics or other altered states. Let the participant set how much detail they give.
• Example language (illustrative): "Tell me as much or as little as feels right today about what happened."
• Watch for: flooding during history-taking. Slow down and use breathing (4.10).

4.5 Explaining the approach

• Purpose: to set realistic expectations.
• Steps: explain the inner healing intelligence, that the medicine is a tool, the alternation between going inward and talking, that experiences may be surprising or non-linear, and what the therapists will and will not do.
• Example language (illustrative): "We'll mostly follow where your experience goes. We won't steer you towards a particular memory."
• Watch for: magical expectations, such as hoping for a cure in one session.

4.6 Intention setting

• Purpose: to orient the process while holding goals loosely.
• Steps: explore what the participant hopes for. Encourage them to trust their own timing. Write the intention down and revisit it before each medicine session.
• Example language (illustrative): "What would you like to bring with you, knowing the experience may take you somewhere else?"
• Watch for: rigid or perfectionist intentions. Reframe them as directions rather than tests.

4.7 Preparing for what to expect

• Purpose: to reduce fear and to normalise difficulty.
• Steps: prepare the participant for trauma memories coming back, emotional intensity, and possible temporary increases in symptoms afterwards. Address specific fears, such as losing their identity or damaging relationships.
• Example language (illustrative): "Feeling worse for a while afterwards doesn't mean it isn't working. We'll be in touch through that."
• Watch for: fears that are not voiced. Ask about them directly.

4.8 Touch agreement and the "stop" signal

• Purpose: advance consent for any physical contact, which is the main protective boundary.
• Steps:
  1. Explain the two kinds of touch the manual allows. Nurturing touch is, for example, holding a hand. Focused bodywork is pressure or resistance the participant pushes against.
  2. The participant decides in advance what touch, if any, they accept.
  3. Teach a "stop" command that will always be honoured, except when touch is needed to prevent physical harm.
  4. State explicitly that there will be no sexual contact.
  5. Write the agreement down and repeat it on the session day. [synthesis: written record]
• Example language (illustrative): "Some people want a hand to hold, some want no touch at all. Both are fine. If you say stop, we stop immediately."
• Watch for: a participant who agrees to everything (assess whether they can refuse at all). Touch beyond the agreement, restraint or pinning, and touch that soothes the therapist rather than the participant are serious red flags; see the Harm account. [source: 2010 manual; CBC 2022]

4.9 Safety agreements and limits

• Purpose: physical and emotional safety on the session day.
• Steps: agree that the participant will stay in the treatment area with the therapists until the session and the next-morning follow-up are complete; that they will stay overnight with an attendant; that a ride home is arranged; and that there will be no harm to self, others or property.
• Example language (illustrative): "On the day, we'll ask you to stay with us in the room until we both agree you're ready."
• Watch for: reluctance about the overnight stay or about naming a ride. Problem-solve this before the session.

4.10 Diaphragmatic breathing and "breathing into" feelings

• Purpose: a self-soothing skill for anxiety early in a session, and a way to stay with intense emotion later.
• Steps: teach slow belly breathing and practise it in session. Then practise directing the breath towards a sensation or feeling ("breathing into" it).
• Example language (illustrative): "Let the breath drop down into your belly… now see if you can breathe right into that tightness."
• Watch for: hyperventilation, or breathing used to avoid feeling. This is not breathwork in the hyperventilation sense. [synthesis: distinction from breathwork]

4.11 Planning social support and disclosure

• Purpose: to protect the participant from judgement and isolation afterwards.
• Steps: discuss whom to tell about taking part, since some people judge MDMA use. Identify supportive people, and confirm the support contact.
• Example language (illustrative): "Who in your life could hear about this without making it harder for you?"
• Watch for: isolation, or relationships that may react with hostility.

4.12 Preparing the setting

• Purpose: a safe, comfortable, uninterrupted space.
• Steps:
  1. Use a private, quiet room that feels like a living room rather than a clinic, while safety equipment and medical readiness stay evident.
  2. Provide reclining furniture, blankets, temperature control, art that is not disturbing, food and art supplies.
  3. Prepare a pre-selected music programme, mostly without lyrics to limit suggestion, and offer silence if the participant prefers.
  4. Offer eyeshades and headphones, which the participant may decline at any time.
  5. Confirm the medical team's emergency contingencies.
• Watch for: eyeshades or blindfolds imposed on someone who does not want them. The participant who was harmed in the Canadian case said she had not wanted blindfolds (see the Harm account). [source: 2010 manual; CBC 2022]

Medicine (experimental) session: therapist conduct

4.13 Alternating inward focus and dialogue

• Purpose: the basic rhythm of the session.
• Steps:
  1. Invite periods of inward focus, with eyeshades and music if the participant wants them.
  2. Alternate these with conversation, roughly balanced overall but varying widely.
  3. Remove the eyeshades for conversation.
  4. Check in periodically, especially after long silences, and gently invite the participant either to share or to go back inside.
  5. At least one therapist is present at all times, and usually both are.
• Example language (illustrative): "You've been quiet for a while. Would you like to say anything, or keep going inside?"
• Watch for: a participant who talks to avoid going inward, or one who goes silent into isolation. The manual advises checking in earlier with someone who tends to isolate. [source: 2010 manual]

4.14 Following versus gently guiding

• Purpose: to support self-direction while gently addressing avoidance.
• Steps:
  1. By default, follow the participant.
  2. If they intellectualise, "get ahead of" the experience, get stuck or keep avoiding, offer an option rather than a directive.
  3. Redirect talk that seems defensive or distracting.
  4. With people who intellectualise, guide them back inward sooner.
• Example language: "would you be willing to…" is the manual's model phrasing [2010 manual]. Illustrative continuation: "…put the eyeshades back on and see what comes?"
• Watch for: your own agenda creeping in. If an invitation is declined, accept that.

4.15 Staying with traumatic material

• Purpose: processing without retraumatisation.
• Steps:
  1. When memories surface, stay empathically present.
  2. Help the participant stay with the feelings rather than suppress or escape them.
  3. Ask about the content if it helps, link past and present, and invite awareness of the body.
  4. Remind the participant of their strengths, such as their self-soothing skills and the fact that they have already survived.
• Example language (illustrative): "You're safe here with us now. Can you let yourself feel that, and notice where it lives in your body?"
• Watch for: dissociation or derealisation that blocks processing; if it appears, move to 4.16.

4.16 Stepwise response to rising distress

• Purpose: the least intrusive response that works. Move to the next step only if needed.
• Steps (in the manual's order):
  1. Invite the participant to notice bodily sensations.
  2. Encourage breath-based presence (4.10).
  3. With permission, offer gentle hand contact (4.17).
  4. Explore the images or thoughts that come with the distress.
  5. Periodically return attention inward.
  6. As a last step, use focused bodywork (4.18).
  7. Verbal reassurance and encouraging expression can be used throughout.
  8. If severe anxiety persists, medical rescue measures are the medical team's decision. The manual describes these as rarely needed.
• Example language (illustrative): "Let's just stay with your breath for a moment. Would it help if I held your hand?"
• Watch for: skipping steps; touch offered before breath and words have been tried.

4.17 Nurturing touch

• Purpose: comfort and grounding, for example holding a hand.
• Steps:
  1. Only within the advance agreement (4.8).
  2. Ask in the moment as well.
  3. Stop immediately on "stop".
  4. Make sure it is visible to the co-therapist and on the recording. [synthesis: visibility]
• Example language (illustrative): "May I put my hand on your shoulder?"
• Watch for: risk flag. Prolonged full-body holding, cuddling or "spooning" is not what the manual describes. CBC reports that such contact in the Canadian case was outside what the manual allows (Harm account). Touch that escalates over a session, or that the therapist initiates repeatedly, needs supervision review. [source: 2010 manual; CBC 2022; synthesis]

4.18 Focused bodywork

• Purpose: to help release emotion or physical tension that stays blocked rather than being processed naturally. It is used only after the gentler steps.
• Steps:
  1. Ask permission.
  2. Offer resistance or pressure the participant can push against, at a spot they choose, while they breathe into the sensation.
  3. The participant leads the intensity.
  4. Stop instantly on request.
  5. Debrief afterwards. Detailed steps are in an appendix to the manual that was not available. [uncertain]
• Example language (illustrative): "Would you like to push against my hand there? You're in charge. Say stop and I stop."
• Watch for: risk flag. Restraining, pinning, holding someone down or covering the mouth are not focused bodywork. In the Canadian case MAPS itself provisionally found that the therapists "substantially deviated" from the manual (CBC). Never use bodywork with someone who has not explicitly agreed, or who is dissociating and cannot consent in the moment. [synthesis on in-the-moment capacity]

4.19 Working with self-judgement, guilt and conflicting feelings

• Purpose: to support the participant as old self-blame shifts.
• Steps: when anger at an abuser, self-forgiveness or guilt emerge in conflict, reflect them and invite the participant to stay with both sides. Decide case by case whether to intervene. Help them see relationships more realistically, without harsh judgement of themselves or others.
• Example language (illustrative): "Part of you is furious and part of you still blames yourself. Can both be here for a moment?"
• Watch for: the therapist taking sides or interpreting. Let the participant reach their own conclusions.

4.20 Tailoring to the participant's style

• Purpose: to fit the method to the person's history and defences.
• Steps: with someone who isolates, check in earlier. With someone who intellectualises, guide them inward sooner. Welcome multiplicity (parts) language without pathologising it.
• Watch for: a single standard approach applied to everyone. [source: 2010 manual]

4.21 Ending the session and handover

• Purpose: a safe transition out of the session.
• Steps:
  1. Later in the session, invite more detailed feedback, without pressure; much of it can wait for integration.
  2. Before leaving, the therapists and the medical team assess physical and emotional stability (vital signs are the medical team's role) and judge when the effects have largely subsided.
  3. If it was planned in advance and judged supportive, a significant other may join; otherwise contact can wait until the next day.
• Example language (illustrative): "We don't need to make sense of everything tonight. Let's talk about it in the morning."
• Watch for: pressure to debrief at length; unresolved distress at handover.

4.22 Overnight stay with an attendant

• Purpose: continuity of safety.
• Steps:
  1. The participant stays in a private room with a trained attendant, usually a registered nurse, who listens without interpreting or acting as a therapist.
  2. The therapists stay reachable by phone and can return.
  3. Encourage rest, journalling, art and recording dreams.
• Watch for: the attendant moving into a therapist role, or contact that crosses boundaries after hours. [source: 2010 manual; MAPP1] [synthesis: boundary note]

Integration phase

4.23 Morning-after integrative session

• Purpose: to begin integration and assess how the participant is.
• Steps:
  1. Hold a session of about 90 minutes.
  2. Invite discussion, but do not require it. If the participant prefers to let things unfold silently, respect that, and still assess their emotional state.
  3. Advise rest and avoiding strenuous or overstimulating activity.
  4. Confirm they are driven home.
• Example language (illustrative): "How are you this morning? There's no need to talk through the session unless you want to."
• Watch for: distress or suicidality, and the participant's ability to go home safely. [source: 2010 manual; MAPP1]

4.24 Telephone check-ins

• Purpose: continued support and risk monitoring.
• Steps: make scheduled calls over the two weeks after each medicine session, each with a "since last visit" C-SSRS screen, plus extra calls if needed. The 2010 manual describes daily calls for a week.
• Watch for: missed calls. If the participant is unreachable, use the support contact. [source: MAPP1; 2010 manual]

4.25 Integrative sessions

• Purpose: to apply insights, changed perceptions and body awareness in daily life.
• Steps:
  1. Start with the participant's own agenda.
  2. Assess how they tolerated the session and any change in symptoms. Explain that change may keep unfolding for days or weeks.
  3. Process emotional distress or cognitive dilemmas.
  4. Introduce focused bodywork if emotions stay blocked, with consent (see 4.18).
  5. Validate insights and reconnect the participant with positive experiences.
  6. Then raise common themes: changed beliefs clashing with family, work or social norms; difficulty explaining the experience; doubt or different emotions the next day; waves of symptoms, which may temporarily worsen; feeling a "failure" when old patterns return; a new sense of calm or self-knowledge.
  7. Encourage writing, listening to session recordings, creative work, dream journals, meditation and yoga.
• Example language (illustrative): "Old patterns coming back is part of the process, not a failure. What did you notice when it happened?"
• Watch for: contraindications to further sessions; new risk. [source: 2010 manual]

4.26 Two ways to handle lingering distress

• Purpose: self-management between sessions.
• Steps: teach the participant to choose between two approaches. When circumstances allow, set aside time to feel the distress fully. When they do not, use grounding: diaphragmatic breathing, a written note to set the feeling aside for later, body-based relaxation (massage, yoga).
• Example language (illustrative): "Now isn't a good time? Write a note to come back to it tonight, then breathe and ground."
• Watch for: constant avoidance, or constant flooding. [source: 2010 manual]

4.27 Planning later medicine sessions, and harm-reduction work outside trials

• Planning later sessions: review earlier experiences and agree new intentions, holding them loosely. Respect the participant's choice about further sessions unless safety argues against it. After a severe adverse reaction, decide on later sessions only after a next-day assessment; the principal therapist decides whether to exclude. [source: 2010 manual]
• Clients using MDMA outside regulated programmes [synthesis throughout]:
  • Do not facilitate, supervise or advise on use.
  • Assess mental state, trauma load and risk.
  • Give general education about medical and psychiatric risks and interaction risks with prescribed medicines; refer to a physician for anything specific.
  • Do safety planning and check for exploitation risk, including touch or sexual boundary violations by "guides".
  • Offer integration sessions using 4.25 and 4.26.
  • Refer to trial programmes or evidence-based PTSD care.

5. Handling problems

[source: 2010 manual where marked; otherwise synthesis]

• Intellectualising or "getting ahead" of the experience. Gently invite the participant back inward, offering a choice rather than an instruction (4.14). [2010 manual]
• Resistance or avoidance. Usually accept the participant's direction. If avoidance keeps recurring, name it gently and explore it together, respecting its protective function. Do not push past it. [2010 manual]
• Panic, fear of losing control, overwhelm. Use the stepwise sequence (4.16): body awareness, breath, reassurance, touch only with permission, encouraging expression. Any medical rescue decision belongs to the medical team. After a severe reaction, decide on later sessions only after a next-day assessment. [2010 manual]
• Dissociation or derealisation that blocks processing. Return to breath and body, orient the participant to the room and to the therapists, and use reassurance. Do not use bodywork while the participant cannot give consent in the moment. [2010 manual; synthesis on consent capacity]
• Persistent distress or new risk after a session. Increase contact: more check-ins, extra sessions, daily meetings. Use C-SSRS screening and the support contact. Hospitalisation is a last resort, and participants are told about it in advance. If a new exclusion appears, stop medicine sessions but continue integration. [2010 manual; MAPP1]
• "Failure" when symptoms return. Normalise waves of symptoms and teach the two-way approach to lingering distress (4.26). [2010 manual]
• Non-adherence (missed calls or sessions, not following safety agreements). Contact the support contact if the participant cannot be reached. Revisit the agreements, and do not hold a medicine session while safety agreements are unresolved. [MAPP1; synthesis]
• Conflict with family or social circle about the experience. Plan disclosure in advance (4.11). In integration, work on changed beliefs that clash with norms. [2010 manual]
• Ruptures (for example the participant feels pushed, misunderstood or touched without wanting it).
  • Stop, acknowledge and apologise without being defensive.
  • Review the recording with your co-therapist and supervisor.
  • Offer the option of a different team.
  • Document what happened.
  • Any touch outside the agreement is a reportable deviation, not just a rupture. [synthesis]
• Idealisation of, or erotic transference towards, a therapist (heightened by the medicine's emotional openness).
  • Name the boundary kindly and clearly.
  • Never act on it, during the trial or after it; the Canadian case involved sex after the sessions ended, while the participant was still in the trial (Harm account).
  • Take it to supervision.
  • Make sure the co-therapist knows. [synthesis; CBC 2022]
• Therapist pressure to report benefit, or discouraging negative reports. ICER reported that some participants said study therapists encouraged favourable reports and discouraged negative ones. In response:
  • Have outcome assessors independent of the therapy team.
  • Invite negative experiences explicitly ("What has been worse or harder?" (illustrative)).
  • Record and report all adverse events, including positive or euphoric effects; the CRL criticised the failure to capture these. [source: ICER via Patsnap 2024; CRL as reported by HCPLive, 15 Sep 2025; synthesis]
• Strong beliefs within the team or community. ICER noted that participants, therapists and investigators held "very strong beliefs" about the treatment. Get supervision from outside the advocacy community, and watch for group pressure on dissent or complaints. [source: Patsnap 2024; synthesis]
• Problems the sources do not address (all synthesis):
  • A client who wants you to "guide" use outside a regulated setting: decline, explain your role, and offer harm reduction and integration support (4.27).
  • Where adolescents, couples or group formats come up: the published protocols covered adults in individual treatment; do not extend the method beyond this.
  • A client who discloses that a therapist harmed them in a psychedelic setting: see the Harm account below.

Harm account

This section reports documented events involving named living people. Every claim is attributed to the source that reports it. Allegations that were not tested in court are labelled as allegations.

What was actually done

The Vancouver phase 2 site (MP4), 2015

• The trial. In early 2015 Meaghan Buisson joined the Health Canada-approved MAPS phase 2 trial in Vancouver (the MP4 site) for PTSD linked to past sexual abuse and assault; her civil claim dates this to January 2015. CBC described her as a hiking guide from Vancouver Island (2022), and reported that she was homeless in Vancouver when she enrolled (2021). [source: CBC, 2021 and 2022; Notice of Civil Claim, 2018]
• The therapists. Richard Yensen and Donna Dryer, a married couple living on Cortes Island, were MAPS sub-investigators. Dryer is a psychiatrist (CBC described her as a clinical assistant professor at UBC). Yensen was an unlicensed therapist. He is not a registered psychologist in B.C., and B.C. does not regulate therapists, so according to CBC no body could investigate or discipline him. The College of Psychologists of B.C. asked him to stop calling himself a psychologist online. [source: CBC, 2021 and 2022]
• The session footage.
  • CBC described footage MAPS recorded during the second experimental session, which lasted at least five hours. It shows the therapists cuddling and spooning Buisson, blindfolding her, and pinning her to the bed with a towel held in her mouth.
  • CBC's April 2022 report summarises the videos as showing the two therapists "physically restraining, cuddling and blindfolding" her.
  • Buisson said she had not wanted blindfolds, and said of the session "That is not therapy."
  • CBC itself had not seen the full session. Lily Kay Ross and David Nickles of Psymposia, who reviewed the full tape, said it showed touch the manual does not allow. [source: CBC, 2022]
• After the sessions. Yensen admitted having sex with Buisson after the sessions ended while she was still in the trial. He said she initiated it and that it was consensual, and he denies that he owed her a doctor–patient duty of care. She alleged sexual assault. [source: CBC, 2021 and 2022]
• Legal and regulatory proceedings.
  • Civil claim (court record). On 28 November 2018 Buisson filed a Notice of Civil Claim in the Supreme Court of British Columbia, Vancouver Registry (file VLC-S-S-1812768), against Yensen and Dryer. MAPS was not a defendant. The claim's allegations, which were never tested at trial:
    • that the couple kept treating her after the trial ended, including after she moved to Cortes Island in 2015, until she left in 2017, while her condition worsened;
    • boundary violations, including an intimate relationship and the sharing of personal information;
    • sexual assault and verbal abuse by Yensen;
    • negligence and breach of fiduciary duty by both defendants.
    • CBC reported that the claim alleged repeated sexual assault with Dryer's knowledge, and that it was settled out of court on undisclosed terms. [source: Notice of Civil Claim (copy hosted by Psymposia); CBC, 2021]
  • Police. In 2019 she made a sexual-assault complaint to the Quadra Island RCMP. The investigation was still open in 2021. By 2022 police had recommended charges, but Crown prosecutors did not approve them. [source: CBC, 2021 and 2022]
  • Medical regulator. Her complaint against Dryer at the College of Physicians and Surgeons of B.C. was unresolved after three years (CBC, 2021) and was still open after more than four years (CBC, 2022). The College did not comment. A later CBC headline reports that a B.C. psychiatrist resigned her licence in connection with the psychedelic therapy study, but the article is not drawn on here. The College's 2022–23 disciplinary-outcomes report has no entry for Dryer. The regulator's outcome is therefore not reported here. [uncertain] A further CBC article on a lawsuit involving the therapists is not drawn on here either. [uncertain]
  • Health Canada. On 4 March 2022 academics and journalists filed a complaint about MAPS's Health Canada-approved trials. Lily Kay Ross submitted it, and bioethicist Emma Tumilty was among the signatories. It alleged, among other things, that some participants became increasingly suicidal and that this was not documented as adverse events. In April 2022 Health Canada said it was reviewing all MDMA trials, with on-site inspections as its priority. MAPS said many of the criticisms were inaccurate. [source: CBC, 8 Apr 2022]
• MAPS's response.
  • In 2019 MAPS said Yensen had an "inappropriate and unethical" relationship with a participant, that Dryer knew of it and did not report it, and that it was cutting ties with the couple. MAPS said its policies forbid sexual relationships between therapists and participants and that there had been "no prior indication" that either therapist would violate this. Its lawyers concluded MAPS was not legally responsible, but it paid Buisson $15,000 for therapy "on a compassionate basis". [source: CBC, 2021 and 2022]
  • In 2022 MAPS said its staff had not viewed the videos until November 2021, six years after they were recorded. It said it was conducting a compliance review of all videos and documentation for each participant, and had provisionally found that the therapists "substantially deviated" from the manual on several occasions. [source: CBC, 2022]

Trial conduct and data integrity (2024)

• ICER, June 2024. ICER called the evidence insufficient and described the trials as essentially unblinded (functional unblinding). It reported that some participants were "encouraged" by study therapists to report favourably and that some therapists "discouraged negative reports". It also cited "very strong beliefs" about the treatment among participants, therapists and investigators. [source: ICER press release 27 Jun 2024; Patsnap Synapse 28 Jun 2024]
• FDA advisory committee, June 2024. The committee voted against efficacy (9–2) and against favourable benefit-risk (10–1). Its consumer representative raised selection bias, functional unblinding and the "potential for some misconduct". According to HCPLive, the committee also noted:
  • no systematic documentation of abuse-related adverse events;
  • inconsistent therapy protocols;
  • participants' vulnerability while acutely impaired;
  • inadequate oversight of therapists. [source: Patsnap Synapse; HCPLive, 15 Sep 2025]
• FDA complete response letter, August 2024 (published September 2025). HCPLive reports the following from the published letter:
  • the trials did not collect adverse events that participants, therapists or investigators considered "positive" or "favorable", and the FDA found unreported events at several sites;
  • the training and safety manual defined adverse events so as to exclude positive or favourable effects, while the MAPP2 protocol did not;
  • about 40% of participants had used MDMA before;
  • durability was not tested beyond 18 weeks;
  • any new trial should include full adverse-event reporting and a third-party data audit.
  • In August 2026 MAPS founder Rick Doblin said "positive adverse events had not been gathered at that time" (Psychedelic Alpha). [source: HCPLive, 15 Sep 2025; Psychedelic Alpha, 12 Aug 2026] [uncertain: the CRL was read through press reports, not the FDA PDF]
• Retractions, August 2024. Psychopharmacology retracted three MAPS-affiliated papers [source: STAT, 11 Aug 2024]. One was the 2020 pooled long-term follow-up of six phase 2 trials (Jerome et al., 237:2485–2497). Its retraction note cites:
  • "protocol violations amounting to unethical conduct" at the MP4 site;
  • the authors' confirmation that they knew of these violations when they submitted the paper, did not tell the journal, and kept the site's data in the analysis;
  • incomplete declaration of MAPS / MAPS PBC competing interests.
  • Allison Feduccia agreed with the retraction (though not with its wording). Michael Mithoefer, Lisa Jerome, Berra Yazar-Klosinski and Rick Doblin disagreed. [source: Springer retraction note] The other two retracted papers appear in search results: the phase 3 design-and-rationale paper and a paper on discontinuing reuptake inhibitors. Their notices are not drawn on here. [uncertain]
• Aftermath. Lykos reportedly cut about 75% of its staff after the CRL. [source: Blossom; GeneOnline headline] [uncertain: not checked in a primary source]

How it caused harm

• Vulnerability during the medicine session.
  • Participants are in a state of emotional openness and attachment, wearing eyeshades, and often have histories of sexual trauma. In this state, touch and restraint can reproduce the original abuse (blindfolding, pinning, gagging) and shut down the ability to say no. [synthesis, consistent with Buisson's account in CBC]
  • Advance touch consent cannot cover actions outside the agreement, and a participant's capacity to object in the moment may be reduced. [synthesis] The FDA advisory committee itself listed participants' vulnerability while acutely impaired, and inadequate therapist oversight, among its concerns. [HCPLive, 2025]
• Power and dependence. Sexual contact by a therapist with a current trial participant exploits the dependence and transference the treatment produces. This is a known mechanism of harm in psychotherapy generally. [synthesis] In the Canadian case the therapist was unlicensed, so no professional regulator had jurisdiction over him. [CBC]
• Treatment outside the protocol. The civil claim alleges that the couple kept treating Buisson privately, in their home community, after the trial ended, while her condition worsened. This is an allegation only. [Notice of Civil Claim] A continuing relationship of this kind falls outside the protocol, the ethics board and the sponsor's monitoring, so none of the trial's safeguards apply. [synthesis]
• Co-therapist failure. MAPS said the co-therapist knew of the sexual relationship and did not report it. [CBC] A two-therapist team protects the participant only if each therapist is independent and willing to report the other; a married or partnered pair may not be. [synthesis]
• Failed oversight. Recordings existed but, according to MAPS, staff did not review them for six years, so the deviations were not caught. [CBC] According to the retraction note, data from the site stayed in published analyses. [Springer]
• Harm to the evidence base and to future patients.
  • ICER and the advisory committee reported pressure to report benefit, discouraged negative reports and functional unblinding. These can hide adverse effects. [ICER; FDA AdComm]
  • Per the CRL as reported, "positive" or "favorable" adverse events were not collected, and the manual's definition of adverse events excluded them. [HCPLive, 2025]
  • The 2022 complaint to Health Canada alleged that increasing suicidality in some participants was not recorded as adverse events. This is an allegation. [CBC, 2022]
  • Each of these distorts the benefit-risk picture on which clinicians and patients rely. [synthesis]
• Most at risk [synthesis]:
  • survivors of sexual abuse;
  • people with strong attachment needs or dissociation;
  • people who idealise the therapist or the movement;
  • people in unstable housing or with little social support (Buisson was reported homeless at enrolment; CBC 2021);
  • people treated by unlicensed or unregulated practitioners;
  • people in settings without an independent second therapist or independent review.

Recognising it today

[synthesis unless marked]

Red flags in a colleague's, a service's or a "guide's" practice:

• touch not agreed in advance, or escalating over a session;
• cuddling, spooning or lying alongside the participant;
• restraint, pinning, holding down, or anything over the mouth or face;
• blindfolds or eyeshades imposed on someone who did not want them [CBC];
• one practitioner alone with a participant under the drug's effects;
• co-therapists who are spouses or partners, or a co-therapist who knows of a boundary violation and stays silent [MAPS statement via CBC; synthesis];
• recordings never reviewed, or sessions not recorded;
• unlicensed practitioners without a regulator [CBC];
• contact, dating or sex after the sessions, or after the study ("we're no longer in a therapy relationship");
• treatment continuing privately after a trial or programme ends, especially in the therapist's home or community [alleged in the civil claim; synthesis];
• invitations to private ceremonies or retreats;
• requests for secrecy;
• therapist self-disclosure of their own drug experiences in order to bond;
• framing distress or objections as "resistance to healing";
• telling participants to report positively;
• reluctance to record adverse events, adverse-event definitions that leave out "positive" effects [CRL via HCPLive], or suicidality not logged as an adverse event [alleged in the 2022 Health Canada complaint, CBC];
• the treatment presented as a movement, with dissent treated as disloyalty.

Rationales and rebrandings to recognise:

• "the medicine needs touch" or "somatic release" used to justify holding or restraint;
• "trust the inner healer" used to override a stated no;
• "integration" used as the label for ongoing intimate contact.

How the published version differs:

• only nurturing touch and focused bodywork, both consented in advance and stopped on "stop";
• an explicit ban on sexual contact;
• two therapists, ideally one woman and one man;
• recording;
• an overnight attendant who does not act as a therapist;
• participant safety above study goals. [source: 2010 manual]

What to do instead and how to help those harmed

• Safeguards if you work in a regulated programme [synthesis unless marked]:
  • a written touch agreement repeated on the session day;
  • no session without both therapists present;
  • co-therapists who are not each other's spouses or partners, each with a written duty to report the other;
  • routine independent review of recordings, not only when someone complains;
  • a written rule against any romantic or sexual contact with current or former participants;
  • a clear end to the therapy relationship when the protocol ends, with handover to independent care rather than private continuation by the trial therapists;
  • outcome assessors who are not on the therapy team;
  • a way for participants to complain outside the team;
  • full adverse-event capture, including positive or euphoric effects and suicidality, with a third-party data audit (as the FDA's CRL asked for any new trial) [HCPLive, 2025];
  • supervision from outside the advocacy community.
• For PTSD outside trials: use established trauma-focused psychotherapies and refer to authorised trials where appropriate. [synthesis; specific therapies not checked in sources for this entry]
• Assessing a client who reports harm in psychedelic work [synthesis]:
  • Believe and document their account.
  • Assess:
    • PTSD symptoms, including new or re-activated sexual-trauma symptoms;
    • dissociation;
    • shame and self-blame ("I agreed to touch");
    • suicidality (C-SSRS or local standard);
    • loss of trust in therapy.
  • Expect betrayal by the therapist and by the community to be part of the injury.
  • Choose an approach that restores control: non-somatic, with no touch, consent at every step and client-set pacing.
  • Avoid re-exposure to similar settings until the client chooses it.
  • Validate that consent given in advance does not cover actions outside it.
• Ethical, reporting and legal duties [synthesis; check local law]:
  • With the client's consent, help them report to any of these:
    • the practitioner's regulator, where one exists (e.g. a medical or psychology college);
    • the trial sponsor;
    • the research ethics board or IRB;
    • the national regulator (Health Canada, FDA);
    • the police, if they wish.
  • Know your mandatory duties: child or vulnerable-adult protection, and in some jurisdictions a duty to report a colleague's sexual misconduct.
  • Keep careful records, and refer to legal advice and sexual-assault support services.
  • Where the practitioner is unregulated (as with Yensen, per CBC), the ethics board, the sponsor, the national regulator, the police and the civil courts may be the only routes. In the Canadian case these were used: a sponsor statement and payment, an RCMP complaint, a complaint to the medical college about the regulated co-therapist, a B.C. Supreme Court claim, and a Health Canada review. [source: CBC, 2021 and 2022; Notice of Civil Claim]

Sources

Sources:

• MAPS: Treatment Manual, MDMA-Assisted Therapy for PTSD (manual page listing v8.1, 22 Aug 2017, and the Adherence Ratings Manual v6)
• MAPS: MDMA-Assisted Psychotherapy for the Treatment of PTSD, A Revised Teaching Manual Draft (Ruse, Mithoefer, Jerome, Doblin, Gibson, revised 10/23/2010)
• MAPP1 phase 3 protocol, Amendment 4 (22 May 2020), ClinicalTrials.gov NCT03537014
• HCPLive: MDMA-assisted therapy NDA resubmitted to FDA for PTSD (10 Aug 2026)
• Psychedelic Alpha: Two years after rejection, Resilient quietly refiles MDMA for PTSD application (12 Aug 2026)
• Psychedelics Today: MDMA NDA resubmitted to FDA (18 Aug 2026)
• Lykos Therapeutics press release: Complete Response Letter for midomafetamine capsules for PTSD (9 Aug 2024, via BioSpace)
• Psychiatric Times: FDA releases complete response letter on declining MDMA-assisted therapy for PTSD (5 Sep 2025)
• HCPLive: FDA releases CRL detailing safety concerns for MDMA-assisted therapy in PTSD (15 Sep 2025)
• Blossom: Resilient Pharmaceuticals stakeholder profile (secondary; accessed Oct 2026)
• Supreme Court of British Columbia: Notice of Civil Claim, Meaghan Buisson (plaintiff) v. Richard Yensen and Donna Dryer, VLC-S-S-1812768 (filed 28 Nov 2018; copy hosted by Psymposia; allegations only)
• CBC News (Bethany Lindsay): As psychedelic therapy goes mainstream, former patient warns of danger of sexual abuse (2021; date inferred, not shown on the page)
• CBC News (Bethany Lindsay): Footage of therapists spooning and pinning down patient in B.C. trial for MDMA therapy prompts review (2022)
• CBC News: Health Canada announces review of all MDMA trials, as complaint alleges major flaws and safety issues (8 Apr 2022)
• College of Physicians and Surgeons of B.C.: 2022–23 Annual Report, Disciplinary Outcomes (no entry for Dryer)
• ICER: Final evidence report on treatment for PTSD, press release (27 Jun 2024)
• Patsnap Synapse: ICER doubles down on critique of Lykos' MDMA therapy (28 Jun 2024)
• STAT: Psychopharmacology retracts MDMA papers (11 Aug 2024)
• Springer: Retraction Note, Psychopharmacology (2020) 237:2485–2497

Further reading (not drawn on; cited only as headlines or not cited; all [uncertain]):

• MAPS manual v8.1 PDF (linked from the MAPS manual page).
• CBC: "B.C. psychiatrist resigns licence" (amp.cbc.ca … 1.6995983).
• CBC: therapists' lawsuit article (… 1.7010981).
• The FDA's own PDF of the complete response letter: not found in searches, so it is cited only through Psychiatric Times and HCPLive.
• The Psychopharmacology retraction notes for the 2020 phase 3 design paper and the reuptake-inhibitor discontinuation paper (PMC11513733, PMC11513749).
• Psychiatric Times and Drug Topics (Feb 2024) on NDA acceptance and Priority Review.
• GeneOnline on staff cuts.

Books and manuals cited:

• Mithoefer, M., Mithoefer, A., Jerome, L., Ruse, J., Doblin, R., Gibson, E., Ot'alora G., M., & Sola, E. (2017). A Manual for MDMA-Assisted Therapy in the Treatment of Posttraumatic Stress Disorder, Version 8.1. MAPS. (Not drawn on.)
• Ruse, J. M., Mithoefer, M. C., Jerome, L., Doblin, R., & Gibson, E. (2010). MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder: A Revised Teaching Manual Draft. MAPS.

Still [uncertain]:

• Whether the FDA has accepted the 2026 resubmission, and its class and goal date. It is reported only through anonymous sources (Psychedelic Alpha), and no company or FDA confirmation was found.
• The FDA's own CRL PDF (its content is cited through press reports).
• The renaming dates for Lykos and Resilient (Blossom only).
• US Schedule I and Australian TGA status: not covered here.
• Any differences between v8.1 and the 2010 manual.
• The focused bodywork appendix.
• The outcome of the CPSBC complaint against Dryer, and the content of the later CBC reports on a licence resignation and a lawsuit.
• Two of the three 2024 Psychopharmacology retraction notices.